The current stock price of IMRA is 16.9094 USD. In the past month the price decreased by -6.06%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.97 | 976.55B | ||
| JNJ | JOHNSON & JOHNSON | 21.15 | 529.01B | ||
| MRK | MERCK & CO. INC. | 12.6 | 275.43B | ||
| PFE | PFIZER INC | 8.09 | 147.20B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.63 | 115.26B | ||
| ZTS | ZOETIS INC | 19.76 | 55.21B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.66 | 22.93B | ||
| VTRS | VIATRIS INC | 5.51 | 14.79B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.19 | 12.01B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.78B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.35B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.22B |
Imara, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Brookline, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. The company is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The firm is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).
The current stock price of IMRA is 16.9094 USD. The price decreased by -2.82% in the last trading session.
IMRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.